Bristol-Myers Sues Merck Over Cancer Immunotherapy Patent
This article is for subscribers only.
Bristol-Myers Squibb Co. accused Merck & Co. of infringing a new U.S. patent for a novel method of cancer-fighting that uses a patient’s own immune system to fight the disease.
“Merck is threatening to exploit that invention,” known as immunotherapy, with a later-developed method of treatment, in violation of a May 20 patent, Bristol-Myers said in a lawsuit filed yesterday in federal court in Wilmington, Delaware. The New York-based company is seeking unspecified damages.